New drug targets Hard-to-Treat cancers with genetic flaw
NCT ID NCT06130553
First seen Jun 24, 2026 · Last updated Jul 14, 2026 · Updated 4 times
Summary
This study tests a new drug called AZD3470 in people with advanced solid tumors that lack a gene called MTAP. The drug works by blocking a protein that cancer cells need to grow. The trial will check if the drug is safe, tolerable, and effective, both alone and with other cancer treatments. About 334 adults will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD3470 (a targeted drug that blocks a protein called PRMT5, which helps cancer cells grow)
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced cancers that have a specific genetic flaw (MTAP deficiency).
- What could go wrong
- This is an early, first-in-human trial, so the drug may not work or could cause unexpected side effects. The results may not apply to all cancer types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS THAT ARE MTAP DEFICIENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
RECRUITINGSan Francisco, California, 94143, United States
-
Research Site
WITHDRAWNWest Hollywood, California, 90048, United States
-
Research Site
RECRUITINGNew Haven, Connecticut, 06510, United States
-
Research Site
RECRUITINGBaltimore, Maryland, 21231, United States
-
Research Site
RECRUITINGPortland, Oregon, 97239, United States
-
Research Site
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
Research Site
RECRUITINGProvidence, Rhode Island, 02903, United States
-
Research Site
RECRUITINGFairfax, Virginia, 22031, United States
-
Research Site
RECRUITINGMelbourne, 3000, Australia
-
Research Site
RECRUITINGBeijing, 100142, China
-
Research Site
RECRUITINGChengdu, 610041, China
-
Research Site
RECRUITINGShanghai, 200433, China
-
Research Site
NOT_YET_RECRUITINGWuhan, 430030, China
-
Research Site
NOT_YET_RECRUITINGVillejuif, 94805, France
-
Research Site
RECRUITINGChūōku, 104-0045, Japan
-
Research Site
RECRUITINGKashiwa, 227-8577, Japan
-
Research Site
RECRUITINGAmsterdam, 1066CX, Netherlands
-
Research Site
RECRUITINGSeoul, 03080, South Korea
-
Research Site
RECRUITINGSeoul, 06351, South Korea
-
Research Site
RECRUITINGBarcelona, 8035, Spain
-
Research Site
RECRUITINGMadrid, 28027, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a novel drug combo outperform standard chemo for lung cancer?
- Can a Four-Drug cocktail shrink Hard-to-Treat lung tumors?
- New lung cancer drug aims to match Keytruda's success
- Targeted drug shows promise for Gene-Driven lung cancers
- Engineered virus plus immunotherapy aims to outperform chemo in advanced lung cancer
- New drug duo aims to tackle Hard-to-Treat cancers